← Olema Pharmaceuticals, Inc. (OLMA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Olema Pharmaceuticals, Inc. (OLMA)
Pharmaceutical Preparations · market cap $789M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 3
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Olema Pharmaceuticals (OLMA) is a clinical-stage oncology company focused on breast cancer, with palazestrant as its lead asset in Phase 3 development. The company carries a ~$1B market cap but only ~$52.5M in cash, implying a runway of roughly 3.4 months — a critical near-term liquidity constraint. The pipeline also includes OP-1250 in Phase 2 and a combination arm with ribociclib in Phase 3 for hormone receptor-positive breast cancer.
The catalyst path
- 2026-10-31 (est.)Phase 3 · Palazestrantimp 9/10
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| OP-1250 | Phase 2 | Hormone Receptor Positive Breast Carcinoma |
| Palazestrant | Phase 3 | Breast Cancer |
| Ribociclib | Phase 3 | Breast Cancer |
Price & technical context
3-month
-34.6%
6-month
-45.3%
12-month
-15.5%
52-wk range
$7.77–$35.83
vs 50-day MA
-21.5%
vs 200-day MA
-49.0%
Realized vol
113.0%
Max drawdown
-77.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OLMA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.